Skip to main content
Top
Published in: Trials 1/2022

Open Access 01-12-2022 | Research

Principles and recommendations for incorporating estimands into clinical study protocol templates

Authors: Helle Lynggaard, James Bell, Christian Lösch, Amel Besseghir, Khadija Rantell, Volker Schoder, Vivian Lanius

Published in: Trials | Issue 1/2022

Login to get access

Abstract

Clinical study protocols are the foundation of good clinical studies. Prospective and multidisciplinary collaboration that pays attention to the design of all components of the study protocol can ensure that a clinical study will answer the research questions posed in a reliable manner that is meaningful for decision-makers and patients. The ICH E9(R1) addendum on estimands and sensitivity analysis in clinical trials provides a framework for clinical study planning to ensure alignment between study objectives, design, conduct, and analysis. The estimand or clinical question posed can be regarded as the backbone of the study and the clinical study protocol should reflect estimands accordingly. In practice, stakeholders are still learning how to embrace the estimand framework and how it impacts studies and study documents. In this paper, we anticipate that a protocol structure centred around estimands, or objectives rather than endpoints alone will prevail for all types of studies. To assist sponsors during this paradigm shift, this paper provides discussion and guidance for implementing the estimand framework in protocol templates.
Appendix
Available only for authorised users
Literature
7.
go back to reference Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, et al. SPIRIT 2013 Explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.CrossRef Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, et al. SPIRIT 2013 Explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.CrossRef
14.
go back to reference Darken P, Nyberg J, Ballal S, Wright D. The attributable estimand: a new approach to account for intercurrent events. Pharm Stat. 2020;19:626–35.CrossRef Darken P, Nyberg J, Ballal S, Wright D. The attributable estimand: a new approach to account for intercurrent events. Pharm Stat. 2020;19:626–35.CrossRef
16.
go back to reference ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials. Step 2b draft guideline, August 2017. ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials. Step 2b draft guideline, August 2017.
Metadata
Title
Principles and recommendations for incorporating estimands into clinical study protocol templates
Authors
Helle Lynggaard
James Bell
Christian Lösch
Amel Besseghir
Khadija Rantell
Volker Schoder
Vivian Lanius
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Trials / Issue 1/2022
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-022-06515-2

Other articles of this Issue 1/2022

Trials 1/2022 Go to the issue